Renal damage in the SHR/N-cp type 2 diabetes model: Comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker

Laboratory Investigation

Volumn 83, Issue 9, 2003, Pages 1267-1277

  Gross, Marie Luise ^a   Ritz, Eberhard ^a   Schoof, Arne ^a   Helmke, Burkhard ^a   Parkman, Amy ^b   Tulp, Orien ^c   Münter, Klaus ^d   Amann, Kerstin ^e  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b DREXEL UNIVERSITY   (United States)

^c ARUP   (United Kingdom)

^d BAYER AG   (Germany)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DARUSENTAN; DESMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TRANDOLAPRIL; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM CELL; GLOMERULOSCLEROSIS; GLOMERULUS CAPILLARY; KIDNEY INJURY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT STRAIN; URINARY EXCRETION;

ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; IMMUNOHISTOCHEMISTRY; INDOLES; KIDNEY; MALE; PHENYLPROPIONATES; PROLIFERATING CELL NUCLEAR ANTIGEN; PYRIMIDINES; RATS; RECEPTORS, ENDOTHELIN; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA;

EID: 0141590203     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.LAB.0000085188.23709.29     Document Type: Article

References (48)

1. Amann K, Koch A, Hofstetter J, Gross ML, Haas C, Orth SR, Ehmke H, Rump LC, and Ritz E (2001). Glomerulosclerosis and progression: Effect of subantihypertensive doses of α-and β-blockers. Kidney Int 60:1309-1323.
2. Amann K, Kronenberg G, Gehlen F, Wessels S, Orth S, Muenter K, Ehmke H, Mall G, and Ritz E (1998). Cardiac remodelling in experimental renal failure - An immunohistochemical study. Nephrol Dial Transplant 13:1958-1966.
3. Amann K, Münter K, Wagner J, Balajew V, Nabokov A, Hergenröder S, Mall G, and Ritz E (2000). Endothelin A receptor blockade prevents capillary/myocyte mismatch in the heart of uremic animals. J Am Soc Nephrol 11:1691-1699.
4. Amann K, Nichols C, Toernig J, Schwarz U, Zeier M, Mall G, and Ritz E (1996). Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 11:1003-1011.
5. Basile DP (2001). Transforming growth factor-β as a target for treatment in diabetic nephropathy. Am J Kidney Dis 34:887-892.
6. Benigni A, Colosio V, Brena C, Bruzzi I, Bertani T, and Remuzzi G (1998). Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes 47:450-456.
7. Bilous RW, Mauer SM, Sutherland DE, and Steffes MW (1989). Mean glomerular volume and rate of development of diabetic nephropathy. Diabetes 38:1142-1147.
8. Chen S, Hong SW, Iglesias de la Cruz MC, Isono M, Casaretto A, and Ziyadeh FN (2001). The key role of the transforming growth factor-β system in the pathogenesis of diabetic nephropathy. Ren Fail 23:471-481.
9. Coopey LJ, Gellett JS, Davidson EP, Dunlap JA, and Yorek M (2002). Changes in endoneurial blood flow, motor nerve conduction velocity and vascular relaxation of epineurial arterioles of the sciatic nerve in ZDF-obese diabetic rats. Diabetes Metab Res Rev 18:49-56.
10. Cordonnier DJ, Zaoui P, and Halimi S (2001). Role of ACE inhibitors in patients with diabetes mellitus. Drugs 61:1883-1892.
11. Dhein S, Hochreuther S, aus dem Spring C, Bollig K, Hufnagel C, and Raschak M (2000). Long-term effects of the endothelin A receptor antagonist LU135252 and the angiotensin-converting enzyme inhibitor Trandolapril on diabetic angiopathy and nephropathy in a chronic type 1 diabetes mellitus rat model. J Pharmacol Exp Ther 293:351-359.
12. Ellis PA and Cairns HS (2001). Renal impairment in elderly patients with hypertension and diabetes. QJM 94:261-265.
13. El Nahas AM, Bassett AH, Cope GH, and Carpentier JE (1991). Role of growth hormone in the development of experimental renal scarring. Kidney Int 40:29-34.
14. Gassler N, Elger M, Kranzlin B, Kriz W, Gretz N, Hahnel B, Hosser H, and Hartmann I (2001). Podocyte injury underlies the progression of focal segmental glomerulosclerosis in the fa/fa Zucker. Kidney Int 60:106-116.
15. Ghandi M, Olson JL, and Meyer TW (1998). Contribution of tubular injury to loss of remnant kidney function. Kidney Int 54:1157-1165.
16. Goruppi S, Bonventre JV, and Kyriakis JM (2002). Signaling pathways and late-onset gene induction associated with renal mesangial cell hypertrophy. EMBO J 21:5427-5436.
17. Halseth AE, Ensor NJ, White TA, Ross SA, and Gulve EA (2002). Acute and chronic treatment of ob/ob and db/db mice with AICAR decreases blood glucose concentrations. Biochem Biophys Res Commun 21:798-805.
18. Hamada Y, Ikegami H, Meda H, Kawaguchi K, Yamada K, Babaya N, Shibata M, and Ogihara T (2001). Insulin secretion to glucose as well as non glucose stimuli is impaired in spontaneously diabetic Nagoya-Shibsata-Yasuda mice. Metabolism 50:1282-1285.
19. Hargrove GM, Dufresne J, Whiteside C, Muruve DA, and Wong NC (2000). Diabetes mellitus increases endothelin-1 gene transcription in rat kidney. Kidney Int 58:1534-1545.
20. Hocher B, Lun A, Priem F, Neumayer HH, and Raschak M (1998). Renal endothelin system on diabetes: Comparison of angiotensin-converting enzyme inhibition and endothelin-A antagonism. J Cardiovasc Pharmacol 31(Suppl 1):492-495.
21. Hori S, Komatsu Y, Shigemoto R, Mizuno N, and Nakanishi S (1992). Distinct tissue distribution and cellular localisation of two messenger ribonucleic acids encoding different subtypes of rat endothelin receptors. Endocrinology 130:1885-1895.
22. Jesmin S, Sakuma I, Hattori Y, Fujii S, and Kitabatake A (2002). Long-acting channel blocker benidipine suppresses expression of angiogenic growth factors and prevents cardiac remodelling in a type II diabetic rat model. Diabetologia 45:402-415.
23. Kang DH, Anderson S, Kim YG, Mazzali M, Suga S, Jefferson JA, Gordon KL, Oyama TT, Hughes J, Hugo C, Kerjaschki D, Schreiner GF, and Johnson RJ (2001). Impaired angiogenesis in the aging kidney: Potential role of VEGF and TSP-1 in renal disease. Am J Kidney Dis 37:601-611.
24. Katz A, Caramori MLA, Sisson-Ross S, Groppoli T, Basgen JM, and Mauer M (2002). An increase in the cell component of the cortical interstitium antedates interstitial fibrosis in type 1 diabetic patients. Kidney Int 61:2058-2066.
25. Kelly DJ, Skinner SL, Gilbert RE, Cox AJ, Cooper ME, and Wilkinson-Berka JL (2000). Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2) 27 rat. Kidney Int 57:1882-1894.
26. Kimmelstiel P and Wilson P (1936). Intercapillary lesions in glomeruli of kidney. Am J Pathol 12:83-105.
27. Kriz W, Kretzler M, Nagata M, Provoost AP, Shirato I, Uiker S, Sakai T, and Lemley KV (1996). A frequent pathway to glomerulosclerosis: Tuft architecture-podocyte damage-segmental sclerosis. Kidney Blood Press Res 19:245-253.
28. Marette A, Tulp O, and Bukowieki LJ (1991). Mechanism linking insulin resistance to defective thermogenesis in brown adipose tissue of genetically obese rats. Int J Obes 15:823-831.
29. Marsen T, Schramek H, and Dunn MJ (1994). Renal actions of endothelin: Linking cellular signaling pathways to kidney disease. Kidney Int 45:336-344.
30. Miura T, Furuta K, Yasuda A, Iwamoto N, Kato M, Ishiha E, Ishida T, and Tanigawa K (2002). Anti-diabetic effect of nitobegjku in KK-Ay diabetic mice. Am J Chin Med 30:81-86.
31. Orth SR, Amann K, Gehlen F, Unger L, Wagner J, Raschak M, and Ritz E (2000). Adult human mesangial cells (HMCs) express endothelin-B-receptors which mediate endothelin-1 induced cell growth. J Cardiovasc Pharmacol 36(5 Suppl 1):S232-S248.
32. Østerby R (1993). Renal pathology in diabetes mellitus. Curr Opin Nephrol Hypertens 2:465-483.
33. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, and Meyer TW (1997). Podocyte loss and progressive glomerular injury in type 2 diabetes. J Clin Invest 15:342-348.
34. Phillips AO, Babooal K, Riley S, Groene H, Janssen U, Steadman R, Williams J, and Floege J (2001). Association of prolonged hyperglycemia with glomerular hypertrophy and renal basement membrane thickening in the Goto-Kakizaki model of non-insulin-dependent diabetes mellitus. Am J Kidney Dis 37:400-410.
35. Rebibou JM, He CJ, Delarue F, Peraldi MN, Adida C, Rondeau E, and Sraer JD (1992). Functional endothelin 1 receptors on human glomerular podocytes and mesangial cells. Nephrol Dial Transplant 7:288-292.
36. Remuzzi G and Bertani T (1998). Pathophysiology of Progressive nephropathies. N Engl J Med 339:1448-1456.
37. 2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 53:1696-1705.
38. Shimizu A, Kitamura H, Mascua Y, Ishizaki M, Sugisaki Y, and Yamanka N (1997). Rare glomerular capillary regeneration and subsequent capillary regression with endothelial cell apoptosis in progressive glomerulonephritis. Am J Pathol 151:1231-1239.
39. Shimizu A, Masuda Y, Kitamura H, Sugisaki Y, and Vamanaka N (1998). Recovery of damaged glomerular capillary network with endothelial cell apoptosis in experimental proliferative glomerulonephritis. Nephron 79:206-214.
40. Takeda M, Breyer MD, Noland TD, Homma T, Hoover RL, Inagami T, and Kon V (1992). Endothelin-1 receptor antagonist: Effects on endothelin- and cyclosporine-treated mesangial cells. Kidney Int 41:1713-1719.
41. Tulp O (1991). Thermogenesis and obesity in the LA/N-cp and SHR/N-cp rat strains. In: Hansen CT, Michaelis OE IV, editors. New models of genetically obese rats for studies in diabetes, heart disease and complication of obesity. Bethesda, MD: Veterinary Resources Branch, National Institutes of Health, 17-25.
42. Tulp O and Weng M (1992). Effect of genetic dilution on development of diabetes, impaired glucose tolerance and in vitro glucose tolerance and in vitro glucose oxidation in La/N-cp x SHR/N-cp F1 hybrid rats. Comp Biochem Physiol 101:403-408.
43. Velasquez MT, Kimmel PL, Miachaelis IV OE, Carswell N, Abraham A, and Bosch JP (1989). Effect of carbohydrate intake on kidney function and structure in SHR/N-cp rats. A new model of NIDDM. Diabetes 38:679-685.
44. Veniant M, Heudes D, Clozel JP, Bruneval P, and Menard J (1994). Calcium blockade versus ACE inhibition in clipped and unclipped kidneys of 2K-1C rats. Kidney Int 46:421-429.
45. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, and Webb DJ (1998). Blockade of endothelin A (ETA) receptor increases endogenous NO generation. Circulation 97:752-756.
46. Weibel ER (1997). Practical methods for biological morphometry: Stereological methods. London: Academic Press, 9-150.
47. Wolf SC, Brehm BR, Gaschler F, Brehm S, Klaussner M, Smykowski J, Amann K, Osswald H, Erley CM, and Risler T (1999). Protective effects of endothelin antagonists in chronic renal failure. Nephrol Dial Transplant 14(Suppl 4):29-30.
48. Zollinger HU and Mihatsch MJ (1978). Diabetic glomerulosclerosis. In: Zollinger HU, Mihatsch MJ, editors. Renal pathology in biopsy. New York: Springer Verlag, 391-399.